Related Experiment Video

Updated: May 4, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers

Henry D Reyes1, Kristina W Thiel, Matthew J Carlson

  • 1Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, 52242, USA, henry-reyes@uiowa.edu.

Molecular Diagnosis & Therapy
|January 10, 2014
PubMed

Insights

This review examines the role of the epidermal growth factor receptor (EGFR)/human EGFR (HER) family in gynecologic cancers. Understanding HER family expression is crucial for developing new diagnostic tools and targeted therapies for endometrial, ovarian, and cervical cancers.

Area of Science:

  • Gynecologic Oncology
  • Molecular Oncology
  • Cancer Biomarkers

Background:

  • Primary gynecologic cancers include endometrial, ovarian, and cervical cancers, with significant global and national health impacts.
  • Ovarian cancer, in particular, has low survival rates for advanced stages, highlighting the need for improved diagnostics and therapeutics.
  • The epidermal growth factor receptor (EGFR)/human EGFR (HER) family is implicated in various solid tumors, but its role in gynecologic malignancies is not fully understood.

Purpose of the Study:

  • To review the current evidence on HER family member expression in gynecologic cancers.
  • To evaluate the potential of HER family members as diagnostic and prognostic indicators.
  • To explore the therapeutic potential of targeting HER family members in gynecologic malignancies.

Main Methods:

  • Comprehensive literature review of studies investigating HER family expression in endometrial, ovarian, and cervical cancers.
  • Analysis of existing data correlating HER family expression with disease stage, grade, and treatment response.
  • Synthesis of evidence regarding the clinical utility of HER family members as biomarkers and therapeutic targets.

Main Results:

  • Expression patterns of HER family members (e.g., EGFR, HER2, HER3, HER4) in gynecologic cancers are variable and sometimes contradictory.
  • The association between HER family expression and clinicopathological features (stage, grade) requires further clarification.
  • Emerging evidence suggests HER family members could serve as potential targets for novel therapeutic strategies.

Conclusions:

  • The role of HER family signaling in gynecologic cancers warrants further investigation.
  • Standardized assessment of HER family expression may improve diagnostic and prognostic accuracy.
  • Targeted therapies directed at the HER family hold promise for improving outcomes in patients with gynecologic cancers.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

913
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K